ロード中...
Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with platinum (cisplatin or carboplatin) in combination with a th...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2500250/ https://ncbi.nlm.nih.gov/pubmed/18827853 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|